Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma | Synapse
March 1, 2026Open Access
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
Key Points
To evaluate the association of surrogate endpoints with survival in patients treated for locally advanced gastric or GEJ adenocarcinoma.
Analyzed data from KEYNOTE-585 trial
Compared neoadjuvant/adjuvant pembrolizumab plus chemotherapy with placebo plus chemotherapy
Found potential associations between pCR, mPR, pDS and survival outcomes
Highlighted the need for further validation of these associations
Abstract
These findings suggest a potential association between pCR, mPR, or pDS and survival in patients with locally advanced gastric or GEJ adenocarcinoma, although further validation is needed.